The 13-week program will offer funding and guidance to up to 12 health tech, medtech and biotech startups working on AI tools.
Johns Hopkins, CareFirst, Techstars launch healthcare AI accelerator Read More »
The goal is to enable specialty care providers to perform genotyping while patients are undergoing routine clinical examination.
Qiagen, AstraZeneca expand companion diagnostic pact beyond cancer Read More »
Increased demand for services helped offset high expenses for hospitals during July, according to analytic solutions firm Strata.
Hospitals boost operating margins in July: report Read More »
CEO Adam Elsesser told investors the company’s focus needs to be on its core thrombectomy business as it cut its sales forecast for 2024.
Penumbra axes virtual reality division, will lay off 71 people Read More »
Armed with new late-stage data on reducing low-density lipoprotein cholesterol, Novartis is positioning its siRNA therapy Leqvio as a preventive treatment for atherosclerotic cardiovascular disease.
Novartis Plots Leqvio Expansion After Lowering Cholesterol in Phase III Study Read More »
En la era digital actual, la posibilidad de recibir SMS online desde cualquier parte del mundo ha adquirido una relevancia significativa. Ya sea para proteger su identidad, evitar el spam o simplemente superar las limitaciones geográficas, disponer de un número de teléfono inter …
¿Cómo obtener el número de teléfono de cualquier país a través de Internet? Read More »
In its legal complaint, filed in the District Court for New Jersey, Regeneron alleges that Sandoz failed to provide it with relevant information required under the Biologics Price Competition and Innovation Act.
Regeneron Sues Sandoz in Federal Court to Block Eylea Biosimilar Read More »
The chair of the House Committee on Oversight and Accountability wants the CEOs of CVS Caremark, Express Scripts and Optum Rx to fix statements they made in a hearing last month that contradicted the committee’s and Federal Trade Commission’s findings.
House Oversight Chair Calls on PBM Execs to Correct Testimonies Read More »
The pharma continued its clinical losing streak on Thursday with the announcement that it is discontinuing late-stage studies of the anti-PD-1 therapy in non-small cell lung cancer and cutaneous squamous cell carcinoma.
Merck Axes Two Keytruda Phase III Cancer Trials Due to Disappointing Data Read More »
In this episode, the third and final conversation of our mini-series on diversity in clinical trials, Lori and guests discuss framing strategies designed to protect DEI initiatives from legal challenges.
Future-Proofing: Inclusive and Protective Patient Strategies Read More »
